Potent Antifungal Activity of Penta-<i>O</i>-galloyl-β-d-Glucose against Drug-Resistant <i>Candida albicans</i>, <i>Candida auris</i>, and Other Non-<i>albicans Candida</i> Species.

"data availability statement chemdraw professional version 16 0 1 4 (77) was used for chemical structures. supporting information available the supporting information is available free of charge at https://pubs acs org/doi"

"The authors declare the following competing financial interest(s): C.L.Q. and L.M. are inventors on a patent pertaining to the use of PGG for the mitigation of fungal infections. L.E.C. and L.W. are a co-founders and shareholders in Bright Angel Therapeutics, a platform company for development of antifungal therapeutics. L.E.C. is a Science Advisor for Kapoose Creek, a company that harnesses the therapeutic potential of fungi."

"This work was supported in part by a grant from the National Institutes of Health, National Center for Complementary and Integrative Health (NCCIH) (R01AT011990 to C.L.Q.) and a graduate student fellowship from The Jones Center at Ichauway to L.M. Y.L. is supported by the CIHR Frederick Banting and Charles Best Canada Graduate Scholarship—Doctoral Awards. L.E.C. is supported by the Canadian Institutes of Health Research Foundation Grant (FDN-154288) and is a Canada Research Chair (Tier 1) in Microbial Genomics & Infectious Disease and co-director of the CIFAR Fungal Kingdom: Threats & Opportunities program."